"Another route might be to raise sufficient funds to take BLT to...

"Another route might be to raise sufficient funds to take BLT to the end of the first quarter of 2014 and focuss on getting positive resutls during 2013 such that SP rises to more than the 4 cent strike price of the 201,309,355 31/12/2013 options. Exersise of these options would bring in 8 million. This would be a placement route with the least dilution but is high risk with consequent uncertainty."

let's face it - if blt, and ddrnai, is to be a going concern, a game changer, then it has to keep it's side of the yet to be signed up deal - positive human clinical data.

i believe the core (and prudent) strategy is, and ought to be, exactly what you describe above DW2, and everything else that comes our way in the meantime will be a bonus. not unrealistic chances of getting these bonuses either, with sentiments in our fields being what they are now.

if we hadn't noticed, many of those chickens we saw in the
early pre clinical study papers have started coming home. and there's no doubt more to come.

one day when they are fat enough one will lay a golden egg. then the market will be impressed and count all the other ddRNAi chooks that might do the same. end of parable.